Exposure group Total N (%) with PE N (%) with PE Crude RR (95% CI) Adjusted RR (95% CI)a
Calcium-based antacids in GW 0-33
No use 6,964 171 (2.5) Reference Reference
Any use 1,863 60 (3.2) 1.3 (1.0-1.7) 1.2 (0.9-1.6)
Low dose (<1 g/day) 959 31 (3.2) 1.3 (0.9-1.9) 1.3 (0.9-1.8)
High dose (≥1 g/day) 893 29 (3.3) 1.3 (0.9-1.9) 1.2 (0.8-1.8)
Low use trajectory 992 30 (3.0) 1.2 (0.8-1.8) 1.2 (0.8-1.7)
High use trajectory 123 3 (2.4) 1.0 (0.3-3.1) N/A
Calcium-based antacids in GW 0-16
No use 8,276 206 (2.5) Reference Reference
Any use 728 26 (3.6) 1.4 (1.0-2.1) 1.3 (0.9-1.9)
Low dose (<1 g/day) 314 16 (5.1) 2.0 (1.2-3.4) 1.8 (1.1-2.9)
High dose (≥1 g/day) 235 7 (3.0) 1.2 (0.6-2.5) 1.1 (0.5-2.4)
Calcium-based antacids in GW 17-33
No use 7,201 185 (2.6) Reference Reference
Any use 1,604 45 (2.8) 1.1 (0.8-1.5) 1.0 (0.7-1.4)
Low dose (<1 g/day) 847 20 (2.4) 0.9 (0.6-1.4) 0.9 (0.6-1.4)
High dose (≥1 g/day) 690 22 (3.2) 1.2 (0.8-1.9) 1.2 (0.8-1.8)
Proton pump inhibitors in GW 0-33
No use 8,502 217 (2.6) Reference Reference
Any use 332 14 (4.2) 1.7 (1.0-2.8) 1.4 (0.8-2.4)
Low dose (≤1 DDD/day) 242 11 (4.6) 1.8 (1.0-3.2) 1.5 (0.8-2.8)
High dose (>1 DDD per day) 85 3 (3.5) 1.4 (0.5-4.2) N/A
Proton pump inhibitors in GW 0-16
No use 8,868 229 (2.6) Reference Reference
Any use 170 6 (3.5) 1.4 (0.6-3.0) 1.1 (0.5-2.6)
Low dose (≤1 DDD/day) 91 4 (4.4) 1.7 (0.6-4.5) N/A
High dose (>1 DDD/day) 53 0 (0.0) N/A N/A
Proton pump inhibitors in GW 17-33
No use 8,544 217 (2.5) Reference Reference
Any use 289 14 (4.8) 1.9 (1.1-3.2) 1.6 (1.0-2.8)
Low dose (≤1 DDD/day) 210 9 (4.3) 1.7 (0.9-3.2) 1.5 (0.8-3.0)
High dose (>1 DDD/day) 57 3 (5.3) 2.1 (0.7-6.3) N/A